Before Getting a FDG-PET Scan for Alzheimer’s: Benefits and Limitations

Learn what an FDG-PET scan can reveal, where it falls short, and how to prepare for the appointment.

Before getting an FDG-PET scan for Alzheimer's, know the tradeoff: it can reveal reduced brain energy use early and help separate Alzheimer's from other dementias, but it is nonspecific, requires radiation and careful preparation, and has narrow insurance coverage. FDG-PET means fluorodeoxyglucose positron emission tomography, a brain scan that measures glucose metabolism as a marker of how actively brain cells are working. It is usually considered after an initial neurologist evaluation and a head CT or brain MRI, when the diagnosis remains unclear. The result works best as one piece of evidence alongside symptoms, cognitive testing, and other biomarkers.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What the scan measures

Alzheimer's typically shows reduced tracer uptake in lateral temporoparietal areas, the precuneus, posterior cingulate, and medial temporal regions, according to the Society of Nuclear Medicine and Molecular Imaging patient guide brain imaging guide. Those patterns reflect lower glucose use in affected networks, not plaques themselves.

The same source notes that PET can show abnormal brain function before cell-loss changes appear on CT or MRI. That timing can aid earlier diagnosis and help track therapy response.

When telling dementias apart matters

Different dementias injure different networks. Frontotemporal degeneration favors frontal and anterior temporal hypometabolism, while Lewy-body disease shows another pattern, reports a 2026 review in the International Journal of Clinical and Medical Research dementia PET review.

For Alzheimer's versus frontotemporal degeneration, studies report about 80-99% sensitivity and 63-98% specificity. Against Lewy-body disease, reported accuracy is about 70-92% sensitivity and 74-100% specificity. A clear pattern can therefore shift care toward the right support, medicines, and safety planning.

What the scan cannot prove

FDG is a nonspecific marker of neurodegeneration. The National Institute on Aging notes that it does not directly image amyloid plaques or tau tangles, unlike amyloid-PET and tau-PET tracers.

That limit matters because low metabolism can occur in several disorders. Ask the ordering clinician whether amyloid or tau testing, spinal-fluid testing, or clinical follow-up is still needed.

How should you prepare and what will it cost?

The injection uses ionizing radiation in a small tracer dose. RadiologyInfo guidance from the Radiological Society of North America and American College of Radiology says patients fast with water only for several hours and coordinate blood-sugar and diabetes medicines because glucose competes with tracer uptake PET preparation guidance.

Medicare covers FDG-PET for dementia only for differential diagnosis of frontotemporal dementia versus Alzheimer's after documented decline and workup, or in an approved clinical trial, under the Medicare coverage rule Medicare dementia PET policy. Other uses, including screening without symptoms, are not covered.

  • Confirm fasting time, water-only rules, and diabetes dosing with the imaging center.
  • Bring a list of medicines, recent CT or MRI scans, and cognitive-test results.
  • Plan rest before the scan, since talking or mental effort can alter brain uptake.
  • Ask who will explain results and next steps.

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.